Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-05-15
DOI
10.1016/s1470-2045(21)00090-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria
- (2019) C Mircea S Tesileanu et al. NEURO-ONCOLOGY
- DNA methylation-based classification of central nervous system tumours
- (2018) David Capper et al. NATURE
- cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”
- (2018) Daniel J. Brat et al. ACTA NEUROPATHOLOGICA
- Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
- (2017) Martin J van den Bent et al. LANCET
- The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis
- (2017) Maarten M J Wijnenga et al. NEURO-ONCOLOGY
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677).
- (2016) James R. Perry et al. JOURNAL OF CLINICAL ONCOLOGY
- Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing
- (2016) Hendrikus J. Dubbink et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors
- (2016) Pierre Bady et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
- (2016) Jan C. Buckner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets
- (2015) Felix Sahm et al. ACTA NEUROPATHOLOGICA
- Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial
- (2015) Hendrikus J. Dubbink et al. NEURO-ONCOLOGY
- Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation ofIDH
- (2014) J. Gregory Cairncross et al. JOURNAL OF CLINICAL ONCOLOGY
- MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951
- (2013) M. J. van den Bent et al. CLINICAL CANCER RESEARCH
- MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status
- (2012) Pierre Bady et al. ACTA NEUROPATHOLOGICA
- Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
- (2012) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations
- (2011) Shani Mulholland et al. INTERNATIONAL JOURNAL OF CANCER
- IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
- (2010) M. J. van den Bent et al. CLINICAL CANCER RESEARCH
- IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
- (2010) C. Houillier et al. NEUROLOGY
- IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas
- (2009) Takuya Watanabe et al. AMERICAN JOURNAL OF PATHOLOGY
- Analysis of the IDH1 codon 132 mutation in brain tumors
- (2008) Jörg Balss et al. ACTA NEUROPATHOLOGICA
- Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide
- (2008) Walter Taal et al. CANCER
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started